Cargando…

Effect of alirocumab dose increase on LDL lowering and lipid goal attainment in patients with dyslipidemia

OBJECTIVES: The objective of this study is to report the dose response in ODYSSEY phase 3 clinical trials of proprotein convertase subtilisin kexin type 9 inhibition with alirocumab in patients not at prespecified lipid goals who received a per-protocol dose increase from 75 every 2 weeks (Q2W) to 1...

Descripción completa

Detalles Bibliográficos
Autores principales:	Kastelein, John J.P., Kereiakes, Dean J., Cannon, Christopher P., Bays, Harold E., Minini, Pascal, Lee, L. Veronica, Maroni, Jaman, Farnier, Michel
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Lippincott Williams & Wilkins 2017
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5400401/ https://www.ncbi.nlm.nih.gov/pubmed/27740972 http://dx.doi.org/10.1097/MCA.0000000000000438

Ejemplares similares

Adherence to Statin Therapy and Attainment of LDL Cholesterol Goal Among Patients with Type 2 Diabetes and Dyslipidemia
por: Alwhaibi, Monira, et al.
Publicado: (2019)

Design and rationale of the ODYSSEY DM-DYSLIPIDEMIA trial: lipid-lowering efficacy and safety of alirocumab in individuals with type 2 diabetes and mixed dyslipidaemia at high cardiovascular risk
por: Müller-Wieland, Dirk, et al.
Publicado: (2017)

Triglyceride concentrations and non-high-density lipoprotein cholesterol goal attainment in the ODYSSEY phase 3 trials with alirocumab
por: Vallejo-Vaz, Antonio J, et al.
Publicado: (2020)

LDL-cholesterol goal attainment under persistent lipid-lowering therapy in northeast China: Subgroup analysis of the dyslipidemia international study of China (DYSIS-China)
por: Zheng, Wen, et al.
Publicado: (2017)

Efficacy and Safety of Alirocumab in Patients with Heterozygous Familial Hypercholesterolemia not Adequately Controlled with Current Lipid-Lowering Therapy: Design and Rationale of the ODYSSEY FH Studies
por: Kastelein, John J. P., et al.
Publicado: (2014)

Reductions in Atherogenic Lipids and Major Cardiovascular Events: A Pooled Analysis of 10 ODYSSEY Trials Comparing Alirocumab With Control
por: Ray, Kausik K., et al.
Publicado: (2016)

LDL-C calculated by Friedewald, Martin-Hopkins, or NIH equation 2 versus beta-quantification: pooled alirocumab trials
por: Ginsberg, Henry N., et al.
Publicado: (2021)

Alirocumab Treatment and Achievement of Non‐High‐Density Lipoprotein Cholesterol and Apolipoprotein B Goals in Patients With Hypercholesterolemia: Pooled Results From 10 Phase 3 ODYSSEY Trials
por: Bays, Harold E., et al.
Publicado: (2017)

Efficacy and safety of alirocumab, a fully human PCSK9 monoclonal antibody, in high cardiovascular risk patients with poorly controlled hypercholesterolemia on maximally tolerated doses of statins: rationale and design of the ODYSSEY COMBO I and II trials
por: Colhoun, Helen M, et al.
Publicado: (2014)

ODYSSEY FH I and FH II: 78 week results with alirocumab treatment in 735 patients with heterozygous familial hypercholesterolaemia
por: Kastelein, John J.P., et al.
Publicado: (2015)

Effects of icosapent ethyl on lipid and inflammatory parameters in patients with diabetes mellitus-2, residual elevated triglycerides (200–500 mg/dL), and on statin therapy at LDL-C goal: the ANCHOR study
por: Brinton, Eliot A, et al.
Publicado: (2013)

Effect of PCSK9 Inhibition by Alirocumab on Lipoprotein Particle Concentrations Determined by Nuclear Magnetic Resonance Spectroscopy
por: Koren, Michael J., et al.
Publicado: (2015)

Type of dyslipidemia and achievement of the LDL-cholesterol goal in chronic kidney disease patients at the University Hospital
por: Sangsawang, Tamon, et al.
Publicado: (2015)

Statin treatment and LDL-cholesterol treatment goal attainment among individuals with familial hypercholesterolaemia in primary care
por: Iyen, Barbara, et al.
Publicado: (2021)

Efficacy and Safety of Alirocumab in Individuals with Diabetes Mellitus: Pooled Analyses from Five Placebo-Controlled Phase 3 Studies
por: Ginsberg, Henry N., et al.
Publicado: (2018)

Effect of physician characteristics and knowledge on the quality of dyslipidemia management and LDL–C target goal achievement in China: Subgroup analysis of the Dyslipidemia International Study
por: Ding, Rongjing, et al.
Publicado: (2017)

PCSK9 inhibition: the way forward in the treatment of dyslipidemia
por: Stoekenbroek, Robert M., et al.
Publicado: (2015)

Changes in LDL-C levels and goal attainment associated with addition of ezetimibe to simvastatin, atorvastatin, or rosuvastatin compared with titrating statin monotherapy
por: Foody, JoAnne M, et al.
Publicado: (2013)

Efficacy and Safety of Alirocumab in Patients with Heterozygous Familial Hypercholesterolemia and LDL-C of 160 mg/dl or Higher
por: Ginsberg, Henry N., et al.
Publicado: (2016)

Attaining Goals Through Partnerships
por: Ramirez, Julio J.
Publicado: (2003)

Low LDL-C goal attainment in patients at very high cardiovascular risk due to lacking observance of the guidelines on dyslipidaemias
por: Vrablík, Michal, et al.
Publicado: (2023)

LDL-C goal Attainment Among Patients Newly Diagnosed With Coronary Heart Disease or Diabetes in a Commercial HMO
por: Nag, Soma S., et al.
Publicado: (2007)

Effects of extended-release niacin/laropiprant, simvastatin, and the combination on correlations between apolipoprotein B, LDL cholesterol, and non-HDL cholesterol in patients with dyslipidemia
por: Farnier, Michel, et al.
Publicado: (2014)

Prevalence of Dyslipidemia and Lipid Goal Attainment in Statin-Treated Subjects From 3 Data Sources: A Retrospective Analysis
por: Jones, Peter H., et al.
Publicado: (2012)

Utilization of statins and LDL-cholesterol target attainment in Turkish patients with type 2 diabetes - a nationwide cross-sectional study (TEMD dyslipidemia study)
por: Bayram, Fahri, et al.
Publicado: (2020)

Regional Variations in Alirocumab Dosing Patterns in Patients with Heterozygous Familial Hypercholesterolemia During an Open-Label Extension Study
por: Langslet, Gisle, et al.
Publicado: (2020)

Update on the clinical utility of fenofibrate in mixed dyslipidemias: mechanisms of action and rational prescribing
por: Farnier, Michel
Publicado: (2008)

Assessment of the 1% of Patients with Consistent < 15% Reduction in Low-Density Lipoprotein Cholesterol: Pooled Analysis of 10 Phase 3 ODYSSEY Alirocumab Trials
por: Bays, Harold E., et al.
Publicado: (2018)

Treatment patterns and low-density lipoprotein cholesterol (LDL-C) goal attainment among patients receiving high- or moderate-intensity statins
por: Fox, Kathleen M., et al.
Publicado: (2017)

LDL-cholesterol change and goal attainment following statin intensity titration among Asians in primary care: a retrospective cohort study
por: Fang, Hao Sen Andrew, et al.
Publicado: (2021)

Do acute coronary events affect lipid management and cholesterol goal attainment in Germany?: Results from the Dyslipidemia International study II
por: Gitt, Anselm K., et al.
Publicado: (2018)

Lipid goal attainment in diabetes mellitus patients after acute coronary syndrome: a subanalysis of Dyslipidemia International Study II-China
por: Guo, Tongshuai, et al.
Publicado: (2023)

Lipid‐lowering efficacy and safety of alirocumab in patients with or without diabetes: A sub‐analysis of ODYSSEY COMBO II
por: Leiter, Lawrence A., et al.
Publicado: (2017)

ALERT-LDL: adherence to guidelines in the treatment of patients with dyslipidemia
por: Bosso, Giorgio, et al.
Publicado: (2021)

Assessment of patient knowledge of diabetic goals, self-reported medication adherence, and goal attainment
por: Whitley, Heather P., et al.
Publicado: (2006)

Reduced Specificity of Personal Goals and Explanations for Goal Attainment in Major Depression
por: Dickson, Joanne M., et al.
Publicado: (2013)

The Interactive Effect of Goal Attainment and Goal Importance on Acculturation and Well-Being
por: Toth-Bos, Agnes, et al.
Publicado: (2020)

Contemporary Management and Attainment of Cholesterol Targets for Patients with Dyslipidemia in China
por: Gao, Fei, et al.
Publicado: (2013)

Ethiopia Successfully Attaining the Millennium Development Goals
por: Haileamlak, Abraham
Publicado: (2015)

Primary Prevention of Alzheimer's Disease: Is It an Attainable Goal?
por: Han, Jee-Young, et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_jat7ua2amb1nvbd3s3qdbaqr1u